Paper Details

  1. Home
  2. Paper Details

Triptolide Inhibits the AR Signaling Pathway to Suppress the Proliferation of Enzalutamide Resistant Prostate Cancer Cells.

Author: CuiYangyan, HanYangyang, HuangRuimin, HuangWeiwei, LeiMing, LiuDandan, LiuJiakuan, YanJun

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study investigated the efficacy of triptolide (TPL), a compound from the Chinese herb <i>Tripterygium wilfordii</i>, in treating castration-resistant prostate cancer (CRPC). TPL was found to inhibit the transactivation activity of both full-length and truncated androgen receptors (ARs) at low doses, reducing cell viability and showing synergistic effects with enzalutamide in inhibiting CRPC cell survival both in vitro and in vivo.
Paper Details　
Original Abstract of the Article :
Enzalutamide is a second-generation androgen receptor (AR) antagonist for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Unfortunately, AR dysfunction means that resistance to enzalutamide will eventually develop. Thus, novel agents are urgently needed to treat this devast...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5479278/

データ提供：米国国立医学図書館（NLM）

Triptolide: A Potential Treatment for Enzalutamide-Resistant Prostate Cancer

This study investigates the potential of triptolide (TPL), a compound extracted from the Chinese herb Thunder God Vine, as a treatment for enzalutamide-resistant prostate cancer. The researchers found that TPL inhibits the activity of the androgen receptor (AR), a key player in prostate cancer development. They demonstrated that TPL, when combined with enzalutamide, can suppress the growth of enzalutamide-resistant prostate cancer cells both in vitro and in vivo.

Triptolide: A New Weapon in the Fight Against Prostate Cancer

This research reveals the potential of TPL as a promising treatment option for enzalutamide-resistant prostate cancer. It’s like a new weapon in the fight against a relentless desert storm – TPL offers a potential solution to the challenges of treating resistant cancer cells. The study’s findings encourage further research into TPL and its potential to improve outcomes for patients with prostate cancer.

Hope on the Horizon: New Treatments for Resistant Prostate Cancer

The study’s findings provide hope for patients with enzalutamide-resistant prostate cancer. It’s like finding water in a desolate desert – TPL offers a new avenue for treatment, potentially extending lives and improving quality of life for these patients. The study’s findings encourage further exploration of TPL as a potential therapeutic agent in the battle against prostate cancer.

Dr. Camel's Conclusion

This study highlights the potential of triptolide as a promising treatment option for enzalutamide-resistant prostate cancer. It’s like a new oasis in the desert – TPL offers hope for patients facing this challenging disease, potentially providing a more effective treatment strategy.

Date :
  1. Date Completed 2018-03-19
  2. Date Revised 2021-12-04
Further Info :

Pubmed ID

28638477

DOI: Digital Object Identifier

PMC5479278

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.